Profund Advisors’s Akebia Therapeutics AKBA Stock Holding History

Profund Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$204K	Sell	147,109 -37,571	-20%	-$51.6K	0.01%	1012
2025 Q4	$297K	Buy	184,680 +80,706	+78%	+$169K	0.01%	878
2025 Q3	$284K	Buy	103,974 +48,912	+89%	+$163K	0.01%	761
2025 Q2	$200K	Buy	55,062 +10,140	+23%	+$27.9K	0.01%	907
2025 Q1	$86.3K	Buy	44,922 +7,252	+19%	+$14.8K	﹤0.01%	963
2024 Q4	$71.6K	Buy	+37,670	New	+$65.4K	﹤0.01%	1089

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Profund Advisors's AKBA Position: Q1 2026 in Review

Profund Advisors reduced its Akebia Therapeutics (AKBA) stake by 20% in Q1 2026, selling an estimated $51.6K and leaving 147,109 shares worth $204K. The position accounts for 0.01% of the portfolio, ranked #1012.

Profund Advisors first reported a position in AKBA in Q4 2024 and has held it in 6 quarters since. The position peaked at $297K in Q4 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

Profund Advisors held 147,109 shares of Akebia Therapeutics worth $204K as of Q1 2026.
Profund Advisors sold 37,571 Akebia Therapeutics shares in Q1 2026, an estimated $51.6K.
Akebia Therapeutics made up 0.01% of Profund Advisors's portfolio in Q1 2026, its #1012 holding.
Profund Advisors first reported a position in Akebia Therapeutics in Q4 2024 and has held it in 6 quarters since.
Profund Advisors's Akebia Therapeutics position peaked at $297K in Q4 2025.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.